SMITHKLINE-STERLING WOULD HAVE 49% OF COMBINED $2 BIL. OTC BUSINESS
This article was originally published in The Tan Sheet
SMITHKLINE-STERLING WOULD HAVE 49% OF COMBINED $2 BIL. OTC BUSINESS centered in North America (with nearly $1 bil. in sales), 22% in Europe, 12% in Latin America, 5% in Australia/New Zealand, 2% in Japan and 10% in other international markets. The merged business will be "number one in OTC medicines worldwide, the market leader in European and international markets, and number four in the U.S.," SmithKline Beecham calculated.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC